Enanta Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.0%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.43next fiscal year
Monitoring Framework
Key Performance Indicators
Zelicapavir (RSV N-Protein Inhibitor) Clinical Progress QuarterlyTarget: Initiate registrational Phase 2b/3 trial in high-risk adults in 4Q 2026 and Phase 2b trial in pediatric patients in 3Q 2026
EDP-978 (Oral KIT Inhibitor) Phase 1 Trial Progress QuarterlyTarget: Report Phase 1 topline data in 4Q 2026
EPS-3903 (Oral STAT6 Inhibitor) IND Filing QuarterlyTarget: File Investigational New Drug (IND) application in 2H 2026
MRGPRX2 Program Development Candidate Nomination QuarterlyTarget: Nominate lead development candidate in 2H 2026
Watch Items
- Zelicapavir Phase 2b/3 Adult Trial InitiationTrigger: First patient dosed in 4Q 2026Action: Monitor clinical trial registry updates and company press releases to confirm timely initiation.
- EDP-978 Phase 1 Topline Data ReadoutTrigger: Topline safety, tolerability, and pharmacokinetics data release in 4Q 2026Action: Evaluate safety profile and tryptase biomarker changes to assess therapeutic potential in chronic spontaneous urticaria.
- Pfizer Patent Litigation Appeal DecisionTrigger: U.S. Court of Appeals for the Federal Circuit decision issued on June 23, 2026, affirming invalidity of Enanta's '953 patentAction: Assess potential financial windfall or royalty implications regarding Pfizer's Paxlovid.
Research as of 19 Jun 2026